Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cizzle Biotechnology Holdings PLC ( (GB:CIZ) ) has issued an announcement.
Cizzle Biotechnology reported progress toward the U.S. commercial launch of its CIZ1B blood test for early lung cancer detection, as North American partner Cizzle Bio Inc. nears completion of validation work with Omni Health Diagnostics in Texas ahead of a planned CLIA accreditation application in the second quarter of 2026. The partners have also revised their financial arrangements, confirming that Cizzle will receive the remaining US$1.81m of initial advance royalty payments by end-2026 and securing an additional minimum US$3.5m in guaranteed royalties from 2031, underpinning at least US$5.9m in contracted income and supporting the long-term rollout of the test across North America.
The most recent analyst rating on (GB:CIZ) stock is a Sell with a £1.50 price target. To see the full list of analyst forecasts on Cizzle Biotechnology Holdings PLC stock, see the GB:CIZ Stock Forecast page.
Spark’s Take on GB:CIZ Stock
According to Spark, TipRanks’ AI Analyst, GB:CIZ is a Neutral.
The score is held down primarily by weak financial performance (pre-revenue, ongoing losses, cash burn, and a sharply reduced equity cushion), with technical indicators also pointing to subdued momentum. Valuation metrics provide limited support due to negative earnings and no dividend.
To see Spark’s full report on GB:CIZ stock, click here.
More about Cizzle Biotechnology Holdings PLC
Cizzle Biotechnology Holdings is a UK-based diagnostics company focused on developing early cancer detection tests. Its lead product is a non-invasive, cost-effective blood test based on the CIZ1B biomarker, which is highly associated with early-stage lung cancer, and it commercialises this technology through royalty-bearing licensing deals and collaborations with cancer care centres.
Average Trading Volume: 367,270
Technical Sentiment Signal: Sell
Current Market Cap: £5.15M
Learn more about CIZ stock on TipRanks’ Stock Analysis page.